Clinical Trials · NCT01821846
Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 64
- Start date
- Nov 2013
- Locations
- 7 sites, South Korea
- Primary endpoint
- The incidence of SADRs (Serious Adverse Drug Reactions)